Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 3-Year EBITDA Growth Rate is 14.10% as of Dec. 2025, which is at its 10-year median of 14.10. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Metis TechBio Co ranks worse than 51.11% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Metis TechBio Co was 14.10% per year. The lowest was 14.10% per year. And the median was 14.10% per year.
Metis TechBio Co (FRA:RO9) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Metis TechBio Co 3-Year EBITDA Growth Rate Related Terms
FRA:RO9 vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Metis TechBio Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's 3-Year EBITDA Growth Rate falls into.
Metis TechBio Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.10% mean?
Metis TechBio Co (FRA:RO9) has a 3-Year EBITDA Growth Rate of 14.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Metis TechBio Co and its competitors. This is near median its historical median of 14.10. Over the past decade, Metis TechBio Co's 3-Year EBITDA Growth Rate has ranged from 14.10 to 14.10. According to the industry distribution chart, Metis TechBio Co ranks #578 out of 1131 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Metis TechBio Co's 3-Year EBITDA Growth Rate too high?
Metis TechBio Co's current 3-Year EBITDA Growth Rate of 14.10% is near median its 10-year median of 14.10. Over the past 10 years, this metric has ranged from a low of 14.10 to a high of 14.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Metis TechBio Co's value of 14.10% is 5.4% below this industry median. Based on the distribution chart, Metis TechBio Co ranks #578 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #578 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Metis TechBio Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Metis TechBio Co's value of 14.10% is 5.4% below this benchmark. Historically, Metis TechBio Co's own 3-Year EBITDA Growth Rate has ranged from 14.10 to 14.10 over the past decade. While the company's 10-year median is 14.10 vs. the industry median of 14.90, Metis TechBio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metis TechBio Co's current 3-Year EBITDA Growth Rate of 14.10% is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Metis TechBio Co and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metis TechBio Co's current 3-Year EBITDA Growth Rate is 14.10%, which is near median its own 10-year median of 14.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current 3-Year EBITDA Growth Rate of 14.10%. The current 3-Year EBITDA Growth Rate is 14.10%, which is near median its 10-year median of 14.10 and 5.4% below the Biotechnology industry median of 14.90. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current 3-Year EBITDA Growth Rate is 14.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
